Abstract

SCREENING OF IGG ANTIBODIES IN HEMODIALYSIS PATIENTS AFTER RECEIVING THE COVID-19 VACCINE

Kamal Faraj Zaed* and Mohamed Ibrahim Shakhtor

ABSTRACT

The COVID-19 pandemic has disproportionately affected patients on dialysis. Patients undergoing hemodialysis have a high mortality rate associated with COVID-19 and this patient population often has a poor response to vaccinations. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to evaluate the IgG antibody response in patients undergoing hemodialysis following doses of COVID-19 vaccination. In our study the number of male patients is higher with 77.5% compared to the female patients 22.5%. The age group of the affected patients is more in 51-60 with 47.5% and lowers in above 71-80 with 7.5%. According to number of dosage, the dosage 1 is 42.5%, 2 is 40% and 3 is 17.5%. Cause of renal failure mainly due to diabetes mellitus (77.5%), hypertension (75%) and anemia (77.5%). Frequency of dialysis more than 2 times is 10% and more than 3 times is 90% and duration of dialysis is higher in (6 to 9) years is 37.5% and lower in greater than 10 years is 2.5%. Frequency of blood transfusion (0-3) times is 62.5% in male and 17.5% in female respectively. In our study IgG range is tabulated from (0.40 to 100) male is 7.5%. From (201 to 300) male is 10% and female is 10%. IgG range is higher from 200 to 450 after the vaccination. Further studies should elucidate the utility of booster vaccinations to foster a stronger and persistent antibody response.

Keywords: Hemodialysis, COVID-19 vaccines, chronic kidney disease.